Translation of "Encephalitis virus" in German

Other diseases such as Leishmania, rabies, Venezuelan equine encephalitis virus and West nile virus are also present in Colombia.

Other feared viruses include the Venezuelan equine encephalitis virus and the Rift Valley fever virus.

The vaccination provides effective protection against infection with the tick-borne encephalitis (TBE) virus.

Regrettably they contribute significantly to the spread of different strains of tick encephalitis and hanta virus.

Ixiaro (given as 2 doses 4 weeks apart) was as effective as the comparator vaccine at triggering the production of antibodies against the Japanese encephalitis virus.

In future, the immune system will be able to produce antibodies quickly and in large numbers when it is exposed to Japanese encephalitis virus again.

A booster dose should also be considered for adults aged above 65 years before any further exposure to the Japanese encephalitis virus.

Hence, primary immunisation should be completed at least one week prior to potential exposure to Japanese encephalitis virus (JEV).

These studies showed that almost all mice that had a Plaque Reduction Neutralization Test titre of at least 1:10 were protected from a lethal Japanese encephalitis virus challenge.

These additional studies showed that protection against Japanese encephalitis virus lasted for at least 2 to 3 years in most people vaccinated with Ixiaro.

Adults from 18-65 years who are likely to be exposed to the Japanese encephalitis virus again or who are at continuous risk of the disease should receive a booster dose of Ixiaro one to two years later and a second booster dose 10 years after the first booster.

Vaccination with Ixiaro should be considered for people who are at risk of exposure to the Japanese encephalitis virus through travel or work.

Recent outbreaks of West Nile virus encephalitis in humans have occurred in Algeria (1994), Romania (1996 to 1997), the Czech Republic (1997), Congo (1998), Russia (1999), the United States (1999 to 2009), Canada (1999–2007), Israel (2000) and Greece (2010).

Ixiaro has been shown to trigger the production of antibodies against the Japanese encephalitis virus in 3 main studies:

The primary immunisation should be completed at least one week prior to potential exposure to Japanese encephalitis virus (JEV) (see section 4.4).

Studies in animals have shown that the vaccine triggers the immune system to produce antibodies against Japanese encephalitis virus that are most often protective.

With both schedules, primary immunisation should be completed at least one week prior to potential exposure to Japanese encephalitis virus (JEV) (see section 4.4).

This project focuses on four families of viruses with an epidemic potential in Europe: influenza, hepatitis E, rabies, diseases caused by rabies-related lyssaviruses and infections caused by the Japanese encephalitis virus or the West Nile virus.

Outbreaks of West Nile virus encephalitis in humans have occurred in Algeria (1994), Romania (1996 to 1997), the Czech Republic (1997), Congo (1998), Russia (1999), the United States (1999 to 2009), Canada (1999–2007), Israel (2000) and Greece (2010).

In a preferred embodiment, a fusion protein (c) is selected from the group consisting of hemagglutinin or influenza A or B viruses, the HA2 component of the hemagglutinin or influenza A or B viruses and peptide analogs thereof, the M2 protein of influenza A viruses, the HEF protein of influenza C viruses, a transmembrane protein of filoviruses such as Marburg virus or Ebola virus, a transmembrane glycoprotein of rabies virus, vesicular stomatitis virus, Semliki Forest virus, tickborn encephalitis virus, a fusion protein of HIV virus, Sendai virus (in particular the F1 component) or respiratory syncytial virus (in particular the gp37 component) and fragments of these viral fusion proteins or of the transmembrane glycoproteins that contain the fusiogenic peptides.

The biomass according to the invention is particularly suitable for the production of tick-borne encephalitis virus (TBE-virus)/virus antigen, if it consists of cell aggregates of avian embryo cells, in particular chick embryo cells, wherein the virus/virus antigen production output is further increased if an oxygen transfer rate of more than 1.60 mmol O2.l-1.h-1, preferably of between 1.65 and 2.40 mmol O2.l-1.h-1, is adjusted.

The biomass according to the invention is particularly suitable for the production of tick-borne encephalitis virus (TBE-virus)/virus antigen, if it consists of cell aggregates of avian embryo cells, in particular chick embryo cells, wherein the virus/virus antigen production output is further increased if an oxygen transfer rate of more than 1.60 mmol O2.1-1.h-1, preferably of between 1.65 and 2.40 mmol O2.1-1.h-1, is adjusted.

The vector as claimed in claim 1, wherein said fusion protein (c) is selected from the group consisting of hemagglutinin of influenza A or B viruses, the HA2 component of the hemagglutinin of influenza A or B viruses, a peptide analogue thereof, the M2 protein of influenza A viruses, the HEF protein of influenza C viruses, a transmembrane protein of filoviruses, a transmembrane glycoprotein of rabies virus, vesicular stomatitis virus, Semliki Forest virus, tickborn encephalitis virus, a fusion protein of HIV virus, Sendai virus, respiratory syncytial virus, and a fragment of said viral fusion proteins or of transmembrane glycoprotein from said viruses from which the transmembrane region is removed.